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Abstract: The starting point of successful hazard assessment is the generation of unbiased and
trustworthy data. Conventional toxicity testing deals with extensive observations of phenotypic
endpoints in vivo and complementing in vitro models. The increasing development of novel materials
and chemical compounds dictates the need for a better understanding of the molecular changes
occurring in exposed biological systems. Transcriptomics enables the exploration of organisms’
responses to environmental, chemical, and physical agents by observing the molecular alterations
in more detail. Toxicogenomics integrates classical toxicology with omics assays, thus allowing the
characterization of the mechanism of action (MOA) of chemical compounds, novel small molecules,
and engineered nanomaterials (ENMs). Lack of standardization in data generation and analysis
currently hampers the full exploitation of toxicogenomics-based evidence in risk assessment. To fill
this gap, TGx methods need to take into account appropriate experimental design and possible
pitfalls in the transcriptomic analyses as well as data generation and sharing that adhere to the FAIR
(Findable, Accessible, Interoperable, and Reusable) principles. In this review, we summarize the
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recent advancements in the design and analysis of DNA microarray, RNA sequencing (RNA-Seq),
and single-cell RNA-Seq (scRNA-Seq) data. We provide guidelines on exposure time, dose and
complex endpoint selection, sample quality considerations and sample randomization. Furthermore,
we summarize publicly available data resources and highlight applications of TGx data to understand
and predict chemical toxicity potential. Additionally, we discuss the efforts to implement TGx into
regulatory decision making to promote alternative methods for risk assessment and to support the
3R (reduction, refinement, and replacement) concept. This review is the first part of a three-article
series on Transcriptomics in Toxicogenomics. These initial considerations on Experimental Design,
Technologies, Publicly Available Data, Regulatory Aspects, are the starting point for further rigorous
and reliable data preprocessing and modeling, described in the second and third part of the
review series.
Keywords: transcriptomics; toxicogenomics (TGx); high throughput; microarrays; sequencing;
experimental design; engineered nanomaterials (ENM); toxicology; alternative risk assessment
1. Introduction
Toxicology aims to understand how various agents can cause harm to humans and the
environment. Traditionally, this means extensive testing strategies including exposure to animal
models and consequently observing the outcome in the means of physical symptoms, or other
measurable parameters. In Europe, the legislative restrictions on animal testing [1] as well as the
advent of ENMs led to the realization that conventional toxicity testing is no longer feasible. Toxicity
assays have been developed originally for bulk chemicals and pharmaceuticals. Instead, ENMs and
other advanced materials are a too broad and novel category to be tested in a similar manner as the
more traditional substances. ENMs are defined as structures with at least one dimension smaller
than 100 nanometers [2]. Thanks to their unique intrinsic properties, nanomaterials are increasingly
utilized in several industrial fields. ENMs are known to interfere with the traditional assays, making
conventional testing approaches less feasible [3–5]. Thus, new strategies are needed to keep up the
pace of the new substances and materials entering the market as well as to support the reduction of
animal experiments. To overcome this bottleneck in the testing of the adverse effects, TGx approaches
have been suggested as a complementing method for traditional safety assessment [6,7]. This has led
to the establishment of several prominent programs in the EU and worldwide aiming to generate
omics-based big data. These could be used in systems biology-based approaches to build predictive
models, simultaneously shifting the focus from in vivo animal testing towards in vitro methodologies
and in silico modeling [8]. Studying gene expression changes in response to a foreign substance or a
compound allows the building of a detailed picture of the organisms molecular levels of alteration and
consequently understanding the MOA of the possible toxicant [7]. Many relatively mature methods for
examining transcriptional changes already exist. Microarrays and RNA-Seq allow relatively thorough
analyses of the transcriptome, and their costs have been steadily decreasing to a level where these
assays are now accessible to most researchers. Moreover, large-scale public databases are constantly
expanding when more and more data are being produced. The emergence of omics technologies
has resulted also in the expansion of methods and tools to handle the complex and large data sets.
What the community of toxicologists, biologists, computational scientists, and other professionals is
still lacking are more unified and consistent strategies for experimental set-up and design, exposure
conditions, and data analysis, all needed steps to efficient interpretation of the outcome and possible
hazard identification. Only using harmonized methodologies and pipelines can aid achieving more
comprehensive cooperation with regulatory agencies. In this review, we focus on how to create,
handle and analyze global, large-scale transcriptomics data from a toxicity point of view, especially
emphasizing the new era of nanomaterial research and hazard assessment.
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Careful planning and study design are key elements for successful transcriptomics experiments.
To obtain valid and unbiased data, as well as to prevent the inclusion of measurement uncertainties
and data that misrepresents the changes in expression, several key steps need to be carefully planned
and handled. To evaluate and ensure significant and reliable outcomes, robust statistical analyses with
a proper amount of sample replicates and appropriate exposure time points and doses are essential
together with proper reference (control) groups [9]. Most of all, recognizing the possible pitfalls in
experimental design and statistical uncertainties is crucial. Furthermore, transparency and proper data
recording are essential for subsequent data analysis and interlaboratory repeatability.
The existing literature about TGx methodologies is currently scattered and focused on particular
facets of the workflow. In this review, we discuss all the relevant aspects of using transcriptomics
in toxicogenomics, which could be utilized to build more robust strategies to further promote
transcriptomics approaches also in regulatory assessment. To this end, in this review series we
cover all the steps needed for performing successful toxicogenomics experimentation, from study
design to robust and comprehensive computational approaches.
2. Replicates and Reference Samples
To afford reliable statistical power to the downstream analysis, the number of sample replicates
is an important factor to consider before any further steps are taken. Some tools and methods
have been suggested to estimate the statistical power of a transcriptomic experiment with respect
to the number of samples included [10–12]. For example, in case of a microarray experiment
aiming at identifying differentially expressed genes, the minimum sample size can be estimated
by means of permutation method proposed by Tibishirami et al. [13]. This allows identification of
the minimum number of samples required to achieve a specific sensitivity (the proportion of truly
differentially expressed genes) at a specified false discovery rate level [14]. In the same way, for
RNASeq analysis the compromise between the number of biological replicates and sequencing depth
should be identified [15]. The price per sample varies depending on the technology [7]. Together with
the possible lack of biological replicates especially of in vivo samples, the price is usually considered as
a limiting factor in transcriptomics. In general, the larger the variance between the biological replicates,
the more replicates are needed. For example, exposure to a genetically similar model organism, such
as cell lines or inbred mouse strains, provides a relatively homogeneous genetic background with
marginal bias derived from the individuals, allowing measurement of fewer replicates as compared
to models with complex and varying genotype or growth conditions [16]. Patient samples, instead,
possess a highly variable genetic background, and thus require correspondingly more replicates to
confirm the measured changes. As with all experiments, in order to understand the change in gene
expression due to the treatment or exposure, a baseline needs to be determined by comparisons against
a negative reference group. It should be also kept in mind that, for example, gender or age might
cause varying responses, especially when patient samples or animals are used to study transcriptional
changes. New materials, such as ENMs, for example, bring additional challenges to the testing
conditions. The number of replicates depends on the experimental setup and there are no universal
standardized guidelines. Transcriptomics datasets derived from ENM-exposed samples deposited in
the GEO database (https://www.ncbi.nlm.nih.gov/geo/) generally comprise a number of replicates
ranging between 3 and 8. For example, Bajat et al. studied the gold nanoparticles (AuNP) toxicity on
in vitro human models. In this study, Caco-2 cells were exposed to spherical gold nanoparticles of two
different sizes at two different concentrations and two time points. They used three replicates for each
experimental condition, and their results indicate that, at high concentrations, smaller AuNPs induce
metal exposure and oxidative stress signaling pathways [17]. Moreover, Poulsen et al. [18] studied
the inflammatory responses of two different multiwalled carbon nanotubes MWCNTs by having an
experimental setup with three doses and three time points and five replicates. The same experimental
set-up was used by Bourdon et al. [19] to investigate the effect of the exposure to carbon black (CB)
nanoparticles in mice. Another example is the study performed by Dymacek et al. [20] on the effect
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of MWCNT in lung inflammation and pathogenesis. The analyzed dataset included four different
doses and four time points with eight replicates for each experimental setup. As classical in vitro
assays might be susceptible to interference originating from the unique physicochemical properties of
ENMs (see section “Other technical considerations”), the most common control includes the addition
of ENMs to the assay components alone, followed by measurement of the intrinsic fluorescence or
absorbance of the ENMs [21]. Thereafter, additional controls are added, such as the inclusion of
the ENM with the analyte, which is again measured, and so on. Additionally, comparison against
positive reference might be beneficial for validating the experimental procedures [22,23]. Positive
reference group could be for example a known toxic substance or bacterial component, depending on
the expected outcome or cellular activation status. For example, in case of ENM, studying the toxic
potential of hollow carbon nanotube structures, a positive or negative control could be an exposure to
well-known substances [22–24]. Experimental planning is an integrated part of TGx analysis. In this
context, given the interdisciplinary nature of TGx, it is crucial to consult experts from complementary
fields to coherently link all the necessary steps of the experiment.
3. Time and Dose Selection
One major step in the toxicological assessment involves the outlining of the relationship between
the amount of exposure and the biological response. Together with the selection of the appropriate
model organism and a sufficient number of replicates, the doses and time points need to be carefully
considered [25].
Dose selection for the TGx experiments largely depends on the exposure route (oral, airways,
dermal, etc.), exposure frequency and duration, exposure system, as well as the model organism.
Different computational models for ENM dose estimation in the respiratory tract of animals and for
in vitro models have been developed [26,27]. As with other substances and pharmaceuticals, also in
the case of ENM the possible toxic effects depend on several factors, and thus no universal guidelines
exist for dose metrics. Poulsen et al. exposed mice with MWCNT by intratracheal instillation with 6,
18, and 54 µg per mouse [28], whereas Wallin et al. exposed mice with titanium dioxide nanoparticles
with dose of 18, 54, and 162 µg per mouse [29]. Kinaret et al. instead, mimicked chronic exposure
model by exposing mice by oropharyngeal aspiration for four consecutive days to 10 and 40 µg of
MWCNT and by inhalation exposure for 4 hours a day for four consecutive days with 6.2–8.2 mg/m3
of MWCNT [30]. Moreover, Scala et al. exposed THP-1, A549 and BEAS-2B cells to eight different
ENMs with 0.1, 0.5, 1, 5, 10, 50, 100, and 500 µg/mL for 48 hours and concluded that the concentration
of 10 µg/mL induced low levels of cytotoxicity and high cell viability, enabling recording of the fine
molecular changes caused by the ENM instead of the more dominant apoptotic and cellular stress
signals [31]. In conclusion, the dose selection requires careful considerations and planning on the
ENM-specific aspects and should be designed distinctively based on the research question.
In toxicology, the dose–response assessment is crucial in determining the dose thresholds in
which a low-toxic substance becomes harmful, or a highly toxic substance does not cause harm. In
more traditional dose–response assessment, to determine the highest dose, which does not cause
statistically significant adverse effects, the No observed adverse effect level dose (NOAEL) can be used
to determine the point of departure (POD) for the chemical. More recently, the benchmark dose (BMD)
approach has been introduced, in which a dose–response model is fitted to the data and the response
rate is recorded. These approaches are dependent on the dose selection and sample size. Traditionally,
these methods require time- and resource-consuming methodologies of biological parameters such as
tumor incidence, cell proliferation, or body weight changes. TGx, instead, provides faster strategies
for determining BMD levels, with less screening and animal experiments [32]. Moreover, the goal of
BMD is to build estimates about safe daily exposure levels, and for this, TGx approach can provide
faster predictions allowing complex modeling of gene expression changes in thousands of features
simultaneously. Further details on BMD modeling can be found in the third part of this review:
“Transcriptomics in toxicogenomics, Part III: Data Modeling”.
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Several efforts have been made to demonstrate that BMD values from transcriptional data are
comparable with apical data [33–37]. TGx analyses are still relatively expensive; thus, a reasonable
strategy to optimize between doses and specific end points of interest needs to be considered. Useful
TGx profiles can be obtained by testing one dose in one time-point, although, in order to cover the
boundaries of toxic effects (i.e., POD), more doses are required [38]. Nonetheless, one dose and one
time point exposures will provide information about specific and direct MOA [39]. Alternatively,
using multiple doses will help to disentangle complex mechanisms of dose-dependent molecular
alteration but will not allow any interpretation of time course, or long-term effects. One dose with
long term follow-up instead, will help to highlight the pathways of recovery. Multiple exposure
time points, as well as doses, are beneficial in defining dose-dependent effects and transcriptional
PODs [40]. To disentangle the kinetic patterns of molecular alterations exerted by an exposure,
analyzing multiple time points becomes of paramount importance. As toxicity testing involves
evaluation of acute phase response as well as possible chronic effects, exposure time points need to be
cautiously considered in order to recognize the course of molecular activities. In general, microarrays
and sequencing experiments provide information about a specific response at a given time. For this
reason, one exposure time point results in only revealing a small fraction of the whole biological
outcome. Additionally, enough dose and time points need to be measured in order to predict long-term
toxic effects through advanced computational approaches and machine learning algorithms [41,42],
as also discussed in detail in the third part of this review. Nonetheless, most of the gene expression
changes are measurable in hours or days after exposure, rather than months or years. Studying the
changes in expression profiles after relatively short exposure to toxicants is useful for investigating
the relationships between acute and chronic mechanisms of toxicity. Furthermore, when relationships
between exposure duration and the produced gene expression profiles are compared, secondary effects
can be identified [43].
Other important issues that need to be considered are the comparable doses applied during the in
vitro and in vivo studies. Before the comparison of the results, one needs to ensure that the tested in
vitro doses are suitably equivalent for the in vivo situation [44]. Especially in the case of ENMs, the
proper dose metrics are not easily defined, with surface area-to-volume ratio having a significant effect
on ENMs properties and reactivity [45].
3.1. Exposures and Sample Quality
Following the ancient dictum “dose makes the poison” , when deciding whether an agent presents
a toxicity concern, exposure assessment is central. Conversely, toxicity testing needs to be done at
biologically realistic concentrations; otherwise, a hazard that is detected may not be meaningful.
For thorough TGx analysis that aims at answering the questions about dose-dependency and safe
limits, it is therefore important to consider multiple exposure doses. Recommendations for dose
and endpoint selection, target organism, route and method of administration, and time of exposure
are indicated in guidelines provided by regulatory entities like the European Commission’s science
and knowledge service and the The Organisation for Economic Co-operation and Development
(OECD) [46]. Before proceeding to the TGx experimentation, other measurements should be considered
to fine-tune proper dose and time selection. For example, controlling viability, confluency, and
cytotoxicity in in vitro models is recommended in order to avoid biased molecular effects caused by
induced apoptotic signaling cascades and excess cellular stress caused by the growth conditions [47].
This might not be simple, as discussed in the subsequent paragraph “Other technical considerations”.
Chemical exposures for toxicological studies need to be performed in a highly controlled manner
and with careful administration of the toxicant. Controlled exposure conditions with minimal effects
derived from different environmental factors are crucial. Changes for example in temperature, pH,
and agglomeration status are all having an impact on the outcome. Again, as an example, much
discussion and arguments about proper testing methods for ENMs have risen due to properties such as
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hydrophobicity, charge, and reactivity, causing for example agglomeration, protein corona formation,
and other unexpected behaviors in biological systems [48].
Furthermore, after successful exposure, before performing extensive microarray or RNAseq
experiments, the quality of the obtained RNA needs to be verified. One important step in sample
processing, together with the proper storage conditions, is the purification of the mRNA samples.
It needs to be ensured that no contamination for example from genomic DNA or RNAse enzymes
will interfere with the analysis. For this, spectrophotometric analysis gives an estimation of RNA
purity and concentration. In order to confirm the integrity of the RNA molecules, more advanced
measurements, such as microcapillary electrophoretic RNA separation, are recommended [49].
In toxicology, the route (exposure pathway) and duration of exposure, together with appropriate
doses and chemical composition of the possible toxicant, affect the chosen exposure method and
model organism. The principles of toxicology exposure can be found in guidelines from governmental
institutions and the European Chemicals Agency (ECHA) and are outside the scope of this review.
3.2. Minimizing the Variation
Undesirable variation caused by technical and other non-biological sources are called batch
effects. Well-known batch effects in transcriptomics data (further discussed in the second part of this
review) include technical, environmental, and individual factors, such as changes in time, personnel,
instruments, sample storage conditions and period, reagent slots, and slides/chips/wells. Technical
artifacts and batch effects cannot be entirely avoided in high-throughput experiments, but careful
design and sample randomization can reduce these effects significantly [50]. Therefore, batches and
other sources of variation should be uniformly distributed across the biological groups [51]. In practice,
after quality check, the samples need to be randomized in a controlled manner. This means, that,
in order to reduce additional biases, samples, slides, and dyes are distributed (organized) to cover
all possible sample combinations [52]. For example, if all control samples are labeled with the same
dye, and treated samples with another dye, the additional effect caused by the labeling cannot be
removed from the data. For this reason, carefully controlled randomization is a necessity. Additionally,
if enough replicates are obtainable, some of the technical biases can be reduced by pooling several
samples together before the experiment. Nonetheless, pooling should not be performed on biological
samples, such as cancer tissue samples of patients, in which the individual differences are of high
importance [25,53].
An often neglected part of transcriptional data management is the accurate recording of the
metadata. This includes recording of all the possible sources of variation and batch effects such as
changes in operators, exposure and procedure dates, sample storage and processing conditions,
sample labeling, dyes, array and slot/position information, changes in reagent slots/batches,
quality measurements, and other possible deviations. In order to ensure replicability of the
experiment and the data analysis, accurate information about the samples need to be recorded and
reported. For this, uniform phenotypic data files are essential, and need to be created as shown
in the example in Table 1. Besides, major public databases such as the Gene Expression Omnibus
(GEO) and ArrayExpress have adopted the Minimum Information About a Microarray Experiment
(MIAME) and Minimum Information about a high throughput SEQuencing Experiment (MINSEQE)
standards [54–56]. Thus, they offer full support for the submission of the genomic experiment data that
these standards define as the minimum information that enables the interpretation and reproducibility
of the results of relevant experiments. Brazma et al., when first proposed the MIAME documentation,
argued that the initial gap in the information related to the quality and reliability of publicly available
microarray data would affect not only the understanding of the outcome of their analysis but also
any future effort to use the stored data for automated data analysis or mining. Furthermore, FAIR
(Findable, Accessible, Interoperable and Reusable) Data Principle guidelines for data management, are
highly recommended, allowing to promote the maximum reuse of research data (see section “Publicly
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available datasets for toxicogenomics” paragraph) [57]. Supplementary standardized information
relevant to the exposure details can further facilitate the reusability of TGx data [58].
Table 1. Example of the phenodata table reporting.
Sample Sample ID Date Material Dose Time Day Array.N Hybr Date Slot Slid Bar Code Operator
12 121 12/03/2019 TiO2 10 24 Cy5 2 18.3. 1_2 757480412533_S05 PKI
3.3. Model Systems
An urgent issue in substituting animal toxicity testing with in vitro experimentations has been
raised by Poulsen et al. [44]. The same concern extends to transcriptomics studies [44,59,60].
Efforts have been made to assess the relevance of the in vitro-based gene expression changes (DNA
microarray as well as RNA-Seq data) to in vivo health effects for chemicals [44,59–61]. The replacement
of in vivo transcriptomics studies with in vitro tests would allow investigation of specific biomarkers
and pathways in a less expensive, more ethical and time-effective manner. In vitro approaches further
allow several time points and doses to be tested with a more reasonable time scale when compared to
extensive, time-consuming in vivo experimentation.
Unfortunately, the task is not simple nor straightforward and, at present, in vitro models cannot
fully replicate in vivo outcomes. For example, the comparison of the in vivo inhalation of rats with the
in vitro exposures using three cell lines (rat lung epithelial cells, rat primary alveolar macrophages and
co-culture of lung epithelial and primary alveolar macrophages) performed for five different types of
nanoparticles indicates only a little correlation in their toxicological behavior [44]. Similar observations
were reported by Warheit et al. and Sayes et al., where the authors assessed the predictability of
the in vitro lung response induced by nano-sized particles (nanoscale zinc oxide and fullerenes) for
in vivo pulmonary hazard potential [62,63]. The authors postulated that these differences may be
caused by the fact that in vivo responses evaluate the toxicity in whole organisms while the in vitro
primarily focuses on the response of a single isolated cell type [44,62–64]. However, on the opposite
side, there are studies with a good agreement between the in vitro and in vivo models in case of the
genotoxic potential of ENMs [65]. This might indicate that proper selection of the cell type as well as
doses and toxicity endpoints would be the crucial factors influencing this comparison [44], although
genotoxicity is a special case involving the singular and universal molecular target, DNA. According to
recommendations by Poulsen et al., another important issue should be the choice of data analysis [44].
They observed that, besides the fact that the regulations of most individual genes measured in the in
vivo and in vitro approaches are different, at the pathway level the common cellular functions (i.e.,
the oxidative stress and fibrosis) were activated. Similarly, Kinaret et al. demonstrated that when
proper data analysis is utilized and the different ENM properties are taken into account, similarities
in transcriptomics responses between mouse lung in vivo and human macrophage cell lines after
ENM exposures can be observed [66]. Despite a little overlap between perturbed genes in vivo and
in vitro was observed, similar molecular and cellular functions were identified. Thus, as a strategy,
they proposed a network-based response modules that project the knowledge from individual genes
to transcriptome-based biological functions [67]. In effect, they postulated that the proper strategy of
data analysis gives the possibility to use the transcriptomic signature measured in vitro to characterize
the outcome for the in vivo scenario [66]. Although some studies highlight the correlation between
exposure systems, more effort is needed to unify the different aspects between the systems, such as
doses and time points, as well as data handling and transcriptomics analyses. Advanced co-culture
systems and 3D models are already extensively explored, and will provide more realistic comparisons
also for toxicogenomics. In this manner it should be possible to gain a more complete appreciation of
differences between in vitro and in vivo TGx outcomes.
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3.4. Other Technical Considerations
Especially in the case of ENMs, many additional technical considerations should be taken into
account. A way to control the quality of the data and to ensure correct measuring procedures is to
validate the assay in order to assess whether or not the target of interest is actually being detected, i.e.,
instead of false-positive results. This is an important step related to standardization in data generation
and analysis, since most optical signal-based assays are subject to a form of assay interference, which
is inadvertently caused by the presence of ENMs within the cell or cytosol [21,68–70]. For example, the
most common molecule used in molecular cell biology assays would be an enzyme, which is a protein.
Ong and colleagues reported that ENMs can bind to proteins and dyes and alter their structure and/or
function [71–77]. They went further to explain that this may adversely influence reactions and cause
significant changes in enzyme activity, fluorescence, and/or the absorbance characteristics of indicator
molecules [71–76,78,79]. Thus, the false positive and/or negative results in conventional screening
assays are due to interference caused by intracellular ENMs that affect the color, chemical activity, light
scattering, etc. [80–82].
Some studies have tried to compensate for this phenomenon by including more controls, or by
verifying one method with another similar method. Examples include the testing of the cytotoxicity
of ENMs such as SiO2 in A549 human alveolar epithelial cells, which was assessed by using two
different toxicity assays [83–86]. As will be discussed below, microarray gene expression results are
commonly validated by quantitative real-time PCR (qPCR). For example, the global transcriptomic
analyses of exposures to surface-modified gold nanoparticles (Au-NPs) were investigated by Grzincic
and colleagues. The authors tested gene expression in human dermal fibroblast (HDF) and prostate
cancer (PIC3) cell lines via RNA microarray, which was confirmed via qPCR [87]. However, assay
interference has been reported for various types of PCR [88–90]. Specifically, Li and colleagues
reported a generalized hindrance of the PCR process [88]. Humes and colleagues concluded that
assay interference occurred when the surface-oxidized multiwalled carbon nanotubes (oxMWCNTs)
inhibited the reverse transcription step of RT-qPCR used to assess gene expression [88–90]. However,
pristine MWCNTs did not cause the same level of interference, which emphasizes the role of surface
chemistry in these types of analyses. Au-NPs were also reported to affect the reverse transcription
efficiency in RT-qPCR [91]. Gao and colleagues later found that the efficiency of the high-fidelity
DNA polymerase (Phusion) was significantly inhibited by some of the major types of metal oxide
NPs (e.g., Fe2O3, ZnO, CeO2, FeO4, Al2O3, CuO, TiO2), but that this did not introduce mutations,
i.e., the overall error rate was not significantly different and single nucleotide polymorphisms were not
introduced [90]. The time-dependent quenching effect of ZnO NPs on fluorescence emissions was also
investigated by Zhang and Lai [92]. These authors went further to determine the interference caused
by other metal oxide nanoparticles in combination with the porphyrin quenching of ZnO NPs, i.e., an
example of interactions between NPs in mixtures. These studies mentioned above support the need to
assess the interactions between, especially metal oxide, intracellular NPs and genetic material, so as to
explain the inconsistencies found in the literature regarding ENM-related TGx and/or toxicity.
In general, Omics techniques have been supposed to exhibit lower interference due to the removal
of the ENMs during the isolation of the analyte [81]. Unfortunately, even if the ENMs are removed by
repeated wash-steps within the isolation procedure, the damage might have already been done when
intracellular or cell membrane-bound ENMs interfere with the biological molecules that are used to
assess toxicity [93]. ENMs could also remain within the cells, or bound to the cell membranes [69,94].
Again, the recommendation is to test for the unintended interactions and to also validate results with
multiple techniques that use different detection methods. In this manner, more stringent conditions for
the use of these types of assays can be employed to prevent misinformation from being produced in
nanotoxicity testing, which has substantial implications for our understanding of, as well as confidence
in, the reported bioactivity of ENMs [21].
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4. Transcriptomic Technologies in Toxicogenomics
4.1. Polymerase Chain Reaction, PCR
PCR is considered as a state-of-the-art method to study gene transcription of known sequences.
The relative change in expression is measured by first synthesizing cDNA from the mRNA transcripts
with reverse transcriptase enzyme and then using PCR to amplify the genes of interest. Quantitative
PCR is a valuable assay for gene expression analysis, but has limits in number of analytes, enabling
assay of only a limited number of genes at a time, making it time consuming and impractical from
a toxicogenomics point of view. However, it is still important, and highly recommended to confirm
and validate the obtained results from high content experiments. PCR-based multiplex methods have
been developed, enabling the amplification of several sequences simultaneously. Nonetheless, from a
toxicogenomics point of view, a genome-wide analysis is needed, for in-depth coverage of the changes
in the whole genome.
4.2. DNA Microarray
DNA microarrays were first proposed by Schena et al. in 1995 [95]. In microarray technology,
thousands of probes are fixed to a surface and samples (targets) are labeled with fluorescent dyes for
detection after hybridization. Laser light is used to excite the fluorescent dyes and collect relative
signal intensities. The hybridization intensity is represented by the amount of fluorescent emission,
which gives an estimate of the relative amount of the different transcripts that are represented.
mRNA from biological samples is reverse transcribed and labeled with one or more fluorescent
dyes. After hybridization, fluorescence is measured separately and captured in two images. These are
merged to produce a composite image, which goes through preprocessing before expression values
are analyzed.
Microarrays have been widely applied in TGx studies and related predictive efforts [30,31,66,96–99].
DNA microarrays can capture relevant transcriptomic responses with concordant biological signals,
independently from the platforms and laboratories [100,101]. A further advantage of microarray technology
is that it is relatively mature, with numerous well-established commercial and open source data
analysis tools [102,103]. Nonetheless, one of the limitations of this technology is the inability to
detect unknown transcripts, as the probes are designed on the basis of known nucleotide sequences.
Moreover, cross-hybridization events may occur when working with highly repetitive genomes, such
as human’s, resulting in an inaccurate observed expression value of the gene compared to the real
expression [104]. From the TGx point of view, distinct sample handling and data preprocessing steps
might limit the reproducibility of the results in different laboratory environments.
4.3. RNA-Sequencing
Although the advent of high-throughput hybridization-based technologies, such as DNA
microarrays, significantly boosted the generation of large scale gene expression profiles, the recent
advances in sequencing technologies further improved such capability. In fact, the so-called
Next-Generation Sequencing (NGS) technologies are currently employed in multiple fields of the
life sciences, including the toxicogenomics. In this context, the RNA-sequencing (RNA-Seq) allowed
overcoming the technical limitations imposed by the hybridization-based techniques. For instance,
the RNA-Seq allows the detection of gene expression with increased dynamic range, solving the
problem of probes saturation for highly expressed transcripts [105]. Furthermore, it does not need
a priori knowledge of the genomic sequence of the studied organism and it does not suffer from
the above mentioned cross-hybridization events, especially in the analysis of complex genomes. As
a consequence, RNA-Seq allows to perform a de novo transcript discovery in order to 1-identify
unannotated transcripts, and 2-characterize new transcripts generated by alternative splicing [106].
Conversely, an appropriate analysis plan should be employed in order to avoid or mitigate certain
biases that could occur during the data management and analysis. For instance, previous works
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showed that standard normalization procedures can affect the sensitivity of the differential expression
analysis, reflecting the behavior of a relatively small number of either high-count or ubiquitous
genes [107,108]. RNA sequencing typically produces bigger and more complex data, which need longer
time and more sophisticated analytical approaches, as compared for instance with DNA microarray
experiments. Although TGx experiments are increasingly employing transcriptome profiling, the
analysis pipelines are still far from being standardized. To date, a benchmark of the optimal analytic
procedures in the transcriptome profiling in TGx experiments has not been formulated. More recently,
the reduction of the costs for the analysis of a single transcriptome made possible the accomplishment
of big scale studies, carried out by international programs, such as CMAP, TOX21, and LINCS1000
aimed at understanding the responses of hundreds of cell models upon treatment with several classes
of chemicals/compounds.
4.4. Single Cell RNA-Sequencing
Since the first single-cell RNA sequencing (scRNA-Seq) protocol was published in 2009 [109],
there has been increasing interest in applying this technique in various areas of research, especially in
cellular heterogeneity, such as in tumors [110], the immune system[111], the brain [112], and embryo
development [113], which is often masked in the typical RNA-Seq. In TGx studies, this technique
has been extensively used to analyze drug tolerance in cancer cells[114]. The scRNA-Seq, as its
name indicates, analyses the transcriptome of an individual cell and is mainly used to resolve the
transcriptional heterogeneity and to identify rare cell populations that would otherwise be hidden in
bulk-cell analyses [115–117]. Currently, there are approximately 20 different scRNA-Seq protocols that
have been reported to address various research purposes.
Full-length methods, such as SMART-seq, cover the whole transcriptome and thereby increase
the number of mappable reads as well as the detected genes per cell. This is useful for analyzing genes
that are expressed at low levels [118]. However, one major drawback of full-length methods is that
they do not support multiplexing and thus require intensive cost and labor as each sample should have
their own sequencing library. In contrast, 3’-end counting methods, such as Drop-seq, MARS-seq, and
CEL-seq, only cover the 3’-end of the transcripts [119]. The transcripts, in this case, can be indexed with
barcodes and unique molecular identifiers (UMIs) to allow multiplexing of samples and quantification
of gene expression. However, as the reads are limited to the 3’-end of the transcripts, the overall
number of detected genes per cell is lower than in full-length methods. In terms of single-cell isolation,
all these technologies separate single cells into nanoliter reaction chambers. In the droplet-based
methods, each cell is partitioned in a hydrogel droplet [120]. In microfluidics-based methods, cells
are individually captured on a microfluidic chip, whereas in plate-based methods, individual cells
are placed into wells on a 96-well plate by micropipetting or fluorescence-activated cell sorting [121].
Of all the scRNA-Seq sample preparation platforms, 10X Genomics’ Chromium is one of the most
widely used commercial solutions. It is a droplet-based 3’-end counting system. On the 10X Genomics’
Chromium, each cell is captured in a water-in-oil emulsion droplet that contains a gel bead labeled with
sequencing adapters, 16-nucleotide barcodes for cell identification, 10-nucleotide UMIs for transcript
identification, and poly[T]primers for mRNA capture.
Although there are various scRNA-Seq methods available for different research questions, most
of them adhere to a similar workflow. The first and most important step is the isolation of viable, single
cells from the tissue of interest. Next, the isolated individual cells are lysed and the mRNA molecules
are captured using the poly[T]-primed oligomers that bind to the poly[A] tail of the mRNA. Analysis of
non-poly[A]-tailed mRNA will require more specialised protocols [122,123]. The complementary
DNA (cDNA) is then synthesized by reverse transcription. Depending on each method, the
reverse transcription primers can have additional nucleotide sequences (i.e., barcodes, UMIs, etc.).
Subsequently, the cDNA is amplified to acquire an adequate amount for sequencing by either PCR, or
in vitro transcription. Then, libraries are prepared by pooling and fragmenting the amplified cDNA.
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Libraries are finally sequenced via NGS. The preprocessing, analysis, and interpretation of the data is
a challenging research topic on its own and will be further discussed in later parts.
4.5. High-Throughput Transcriptomics
High-throughput transcriptomics technologies dramatically increase the throughput of gene
expression data generation. In particular, they allow a low-cost profiling of dose responses.
These methods are very diverse and include microarray-based, RNA sequencing-based as well as
other technologies. For example, the L1000 (Library of Integrated Network-Based Cellular Signatures
1000) platform that is used in the LINCS CMAP database uses flow cytometry and labeled beads [124].
It measures only approximately 1000 genes, but these carefully selected “landmark genes” can be
used to predict the expression of nearly 11,000 genes. This illustrates the principle of redundancy
and co-regulation within gene expression. The S1500+ platform designed by the US National
Toxicology Program has 2753 probe sets or genes, including all the L1000 genes [125]. The larger
number of genes is used to improve the accuracy of gene estimation and to measure directly many
toxicologically relevant and pathway-associated genes. The S1500+ platform uses a TempO-Seq
targeted RNA-Seq method [126]. Compared to the 10-20 million counts in a regular RNA-Seq, it only
needs 0.5-3 million reads per profile. An example of an array-based high-throughput platform is the
Affymetrix/ThermoFisher Scientific Clariom GO Screen assay that includes approximately 20,000 gene
ontology-related genes in a 384-multiplex format. In general, the same or very similar methods can
be used to analyze high-throughput and regular expression experiments. If the data is continuous
or array-based, microarray methods and RNA-Seq methods with count data are recommended. Due
to the larger volume of data, automated R/Bioconductor or other workflows need to be run [127].
Here, tools such as eUTOPIA (A solUTion for Omics data PreprocessIng and Analysis) can be helpful
in reducing the coding workload [128].
5. Publicly Available Datasets for Toxicogenomics
The scientific advancement in the toxicogenomics field is strongly dependent on the availability
of high-quality TGx datasets. Thus, in the last years, many efforts have been made to produce good
quality databases such as Chemical Effects in Biological Systems (CEBS) [129,130], Connectivity Map
(CMAP) [131], LINCS 1000 [124], DrugMatrix [132], Open TG-GATEs[98], ArrayExpress [133], and
Gene Expression Omnibus (GEO) [54,134].
CEBS is a comprehensive toxicogenomics resource compiled by the National Center for
Toxicogenomics (NCT) within the National Institute of Environmental Health Science (NIEHS).
It includes the study design, the timeline, the clinical chemistry, and histopathology findings, as
well as microarray and proteomics data from in vivo and in vitro exposure [130]. CEBS freely available
online at http://tools.niehs.nih.gov/cebs3/ui/.
The CMAP project started in 2006 with gene expression profiles of 164 small-molecule compounds
and was later updated to "build 2", containing gene expression profiles from three cultured human
cells treated with 1309 bioactive small molecules, aimed at finding connections among small molecules
sharing a mechanism of action, chemical and physiological processes, diseases, and drugs [131].
The L1000 Connectivity Map is a Library of Integrated Network-based Cellular Signatures
(LINCS) and was created as a large-scale expansion of the original CMAP, in which almost 20,000
small-molecules have been profiled on up to 77 cell lines at 96 hours after the knockdown [124].
The experiments were performed by using the L1000 platform, which aims to capture the greatest
amount of variation while measuring only a subset of 978 genes, named “landmark genes” [124].
This subset of genes was chosen since they are able to capture the greatest proportion of the variance
in expression [124,135,136].
The DrugMatrix dataset contains gene expression response to compound treatments in rat
tissues [132]. Approximately 600 different compounds have been profiled in up to seven different
tissues of rats, representing over 3200 different drug–dose–time–tissue combinations. The dataset
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also provides histopathological, hematologic and clinical chemistry data associated with compound
treatments, allowing specific forms of toxicity to be investigated. The DrugMatrix dataset is available
through the CEBS database using the CEBS Guided Search tools [130].
Open TG-GATEs is a TGx database that stores gene expression profiles and traditional
toxicological data derived from in vivo (rat) and in vitro (primary rat hepatocytes, primary human
hepatocytes) exposure to 170 compounds at multiple doses and time points [98]. The gene expression
data for a test compound were derived from the administration of individual compounds at up
to four dose levels and eight time-points (corresponding to four single-dose studies and four
repeated-dose studies).
ArrayExpress repository stores data from high-throughput functional genomics experiments,
and provides these data for reuse to the research community [133].
Gene Expression Omnibus (GEO) is a public repository for high-throughput microarray and
next-generation sequencing data sets, carried out by the research community. The resource supports
archiving of raw data, processed data and metadata which are indexed, cross-linked, and searchable.
All data is freely available for download in a variety of formats [54,134].
As introduced above, usable, high-quality databases for TGx data are already available. In order
to deal with the growing number of large datasets and to be able to fully utilize the potential of data
sharing in toxicology, more comprehensive and integrated infrastructure should be still created to
handle the data according to the FAIR principles. In practice, this requires proper metadata handling,
unique identifiers, trusted repositories for easy access and data handling, clear usage licenses, and
opportunities for interoperability [57].
6. Regulatory Aspects
The concept of systems biology has been known already for decades, but the emergence of
high-throughput methodologies and omics approaches rapidly expanded in the beginning of the 21st
century. Since then, transcriptional profiling has become a well recognized field of bioscience. Due to
reducing costs and well-established infrastructure, today omics approaches are available for a wide
research community. The ample amount of available omics-based exposure data enables researchers
to combine and interpret complex and large datasets in a meaningful way. Additionally, in Europe,
directives on animal testing limitations and marketing restrictions for example in case of cosmetics,
encourage the development of alternative testing methods.
Toxicogenomics is recognized as a promising approach to characterize biological activity caused
by exposure to different stressors. For example, in the ECHA’s Guidance "Information Requirements
and Chemical Safety Assessment", TGx-related technologies and toxicity testing are discussed in
the context of in vitro data and Adverse Outcome Pathways (AOPs). The guidance states that the
value of the in vitro models in toxicity testing could be increased by incorporating molecular based
markers through the application of proteomic and toxicogenomic approaches [137]. Also the European
Food Safety Authority (EFSA) has recognized the potential of TGx [138]. Moreover, the REACH
(Registration, Evaluation, Authorisation and Restriction of Chemicals) regulation emphasizes the
utilization of TGx approaches in hazard assessment:
“The Commission, Member States, industry and other stakeholders should continue to contribute to
the promotion of alternative test methods on an international and national level including computer
supported methodologies, in vitro methodologies, as appropriate, those based on toxicogenomics, and
other relevant methodologies. The Community’s strategy to promote alternative test methods is a
priority and the Commission should ensure that within its future Research Framework Programmes
and initiatives such as the Community Action Plan on the Protection and Welfare of Animals 2006 to
2010 this remains a priority topic. Participation of stakeholders and initiatives involving all interested
parties should be sought [139].”
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Although ongoing effort is being made in Europe to bring TGx approaches as part of toxicity and
hazard assessment, no formal guidance yet exists. Nonetheless, there are several ongoing projects
to produce frameworks for omics data-based risk assessment: In the European Union, the European
Centre for the Validation of Alternative Methods (ECVAM), an integral part of the Joint Research
Centre (JRC) and Extended Advisory Group for Molecular Screening and Toxicogenomics (EAGMST)
in OECD are working towards TGx approaches for example by using the concept of AOP [140,141].
OECD supports the development and improvement of AOPs with TGx approaches, by filling the
data gaps and supporting the available mechanistic toxicity data. In 2012, the OECD established a
new programme on the development of Adverse Outcome Pathways. Since the beginning of the
programme in 2012, OECD has released 16 publications on AOP, from which seven were published in
the year 2019 [142]. In addition, the European Centre for Ecotoxicology and Toxicology of Chemicals
(ECETOC) has together with ECVAM developed a Transcriptomics Reporting Framework for omics
data processing and analysis [140]. The framework does not dictate the methodology to be used,
but rather lays the basis for what should be reported when performing bioinformatics with the aim
of supporting risk assessment. Thus, the current three-article series provides a basis for refining
and extending the framework with guidelines based on the suggested state-of-the-art methods
and approaches. Importantly, we suggest here a shift in thinking regarding the current focus on
differentially expressed genes in the framework, as will be discussed in detail in Part II of this
article series. Analysis of differentially expressed genes is often coupled to arbitrary p-value limits and
fold-change thresholds, which leads to one of the largest sources of bias within TGx, i.e., the use of
high irrelevant doses.
In the U.S., The National Toxicology Program (NTP), an interagency program composed
by the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes
of Health (NIH), the National Center for Toxicological Research (NCTR) of the Food and Drug
Administration (FDA), and The National Institute for Occupational Safety and Health (NIOSH) of the
Centers for Disease Control and Prevention (CDC), has established a toxicogenomics testing program
consisting of 5-day rodent chemical exposure studies (https://ntp.niehs.nih.gov/whatwestudy/
testpgm/toxicogenomics/index.html—Retrieved 3 March 2020). All the TGx data generated by
this collaboration are stored in the CEBS database and publicly available to the community. The
agencies across continents are also collaborating in scientific advisory boards towards legitimate
validation and international harmonization of testing strategies based on alternative test methods
including TGx [143].
Data for adverse effects and toxicity are classically retrieved from epidemiological studies of
humans or more commonly from experimental systems including in vitro cell culture models and in
vivo animal models. The data generated by traditional toxicity tests are the cornerstone for human
health risk assessment, determined from the identified changes and phenotypic effects. Nonetheless,
new chemicals, and especially the new era of ENMs, require extensive testing and screening, for which
conventional toxicity testing is not optimal. This problem has been widely recognized, and efforts
for integrated approaches together with high-throughput methods and 3R principles aim to identify
early molecular markers and pathways of toxicity. Instead of traditional endpoints, TGx provides a
possibility to test the entire genome of a cell or tissue, and thus, reveal earlier effects leading to toxic
outcomes [40].
Toxicogenomic approaches are supported in EU-programmes such as Framework Programme 7
(FP7) and Horizon 2020 (H2020), but to the best of our knowledge, no specific legislation exists for TGx
approaches. Currently, toxicogenomics approaches can be used to complement more conventional
methods. Required testing methods depend on the chemical and its composition, and in general,
requirements for pharmaceuticals are more demanding than for industrial chemicals and require
extended testing related to efficacy, safety, and quality control. In the European Commission’s Technical
Guidance Document on Risk Assessment, the use of methods such as quantitative structure–activity
relationship (QSAR) in human health risk assessment is recognized as a potentially contributing factor
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only for certain endpoints [144]. Moreover, the guidance states that modeled data should only be used
for risk assessment purposes where it is supported by other strands of evidence [145].
Understandably more investigations are needed to further embed TGx-based evidence in
regulatory decision making. International unification and harmonization of methods and data
generation and sharing is extremely important in developing toxicogenomics approaches for
hazard assessment [146]. Furthermore, in addition to regulatory implementation of TGx, targeting
the industry with the methods as support for safety assessment at early stages of technological
innovation and development (aiming for so called safe by design strategies) may support uptake
into the generally more slow-adapting (as compared to industrial processes) regulatory processes
(https://doi.org/10.1002/smll.201904749).
7. Conclusions
In this first part of the review, we consider the crucial aspects needed to perform unbiased
and reliable toxicogenomics analysis. We discuss the necessary steps for designing the experiments,
deciding the sample groups, timepoints and doses. Furthermore, we discuss the public databases
and transcriptomics related technologies. TGx has a great potential to overcome the limitations of
traditional hazard assessment and to reduce the amount of animal experimentations. Additionally,
when repeatable and reliable transcriptomics results are achieved, TGx approach allows in vitro
methods to be utilized in regulatory toxicology. This includes better utilization of known methods such
as AOPs and dose-response assessment, as well as better characterization of the biological processes
related to QSAR models.
Reliable TGx data are the starting point to elucidate compounds MOA and predicting toxicity.
Even though public TGx datasets can be found, toxicogenomics advancement would benefit from the
availability of more comprehensive gene expression data and toxic endpoint annotations. Open data
access, open protocols and publicly available meta-data annotations are also important to make data
findable, accessible, interoperable and reusable (FAIR Data Principles) [57].
In conclusion, TGx methods are already favored by a wide community of researchers and
pharmaceutical industries to characterize the molecular mechanisms underlying toxicity by the means
of AOPs and to further predict compound toxicity. Furthermore, the field is evolving and currently
working to reduce animal tests by replacing them with in vitro experiments. Developing TGx towards
regulatory decision making depends on multiple technical and conceptual solutions that are currently
coming together [6,147]. It is difficult to say when these methods will replace animal tests, but they
can already be used as convincing supporting evidence. Altogether, TGx will have a strong impact
on in vitro-based workflows in risk-assessment, on drug development strategies and on clinical
decision making.
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